uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

QURE uniQure N.V.

休市中 04-17 16:00:00 EDT

17.58

+0.77

+4.58%

盘后17.65

+0.07+0.41%

19:41 EDT

最高17.89	最低17.02	成交量190.31万
今开17.05	昨收16.81	日振幅5.21%
总市值10.95亿	流通市值7.14亿	总股本6,229万
成交额3,317万	换手率4.68%	流通股本4,064万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure N.V.","latestPrice":17.58,"timestamp":1776456000000,"preClose":16.81,"halted":0,"volume":1903057,"hourTrading":{"tag":"盘后","latestPrice":17.6525,"preClose":17.58,"latestTime":"19:41 EDT","volume":61067,"amount":1073941.9689,"timestamp":1776469286872,"change":0.0725,"changeRate":0.004124,"amplitude":0.012497},"delay":0,"changeRate":0.04580606781677571,"floatShares":40636300,"shares":62291663,"eps":-3.46024,"marketStatus":"休市中","change":0.77,"latestTime":"04-17 16:00:00 EDT","open":17.05,"high":17.89,"low":17.015,"amount":33171754.573060997,"amplitude":0.052052,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.46024,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1776672000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":16.81,"preHourTrading":{"tag":"盘前","latestPrice":17.01,"preClose":16.81,"latestTime":"09:29 EDT","volume":2021,"amount":34537.733988,"timestamp":1776432599999,"change":0.2,"changeRate":0.011898,"amplitude":0.020077},"postHourTrading":{"tag":"盘后","latestPrice":17.6525,"preClose":17.58,"latestTime":"19:41 EDT","volume":61067,"amount":1073941.9689,"timestamp":1776469286872,"change":0.0725,"changeRate":0.004124,"amplitude":0.012497},"volumeRatio":1.0147889948275413,"impliedVol":1.4643,"impliedVolPercentile":0.712},"requestUrl":"/m/hq/s/QURE/tweets","defaultTab":"tweets","newsList":[{"id":"2616585668","title":"Uniqure N.V.盘中异动 股价大跌14.57%报8.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616585668","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616585668?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:31","pubTimestamp":1772548284,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时31分，Uniqure N.V.股票出现波动，股价快速下跌14.57%。截至发稿，该股报8.97美元/股，成交量104.781万股，换手率1.68%，振幅2.86%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.94%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322312497a7df11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322312497a7df11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616966003","title":"FDA要求开展III期试验 uniQure(QURE.US)亨廷顿病基因疗法上市受阻股价重挫约33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616966003","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616966003?lang=zh_cn&edition=full","pubTime":"2026-03-03 09:50","pubTimestamp":1772502622,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基因治疗公司uniQure原本寄望其亨廷顿病候选药物AMT-130能获得美国FDA的加速批准，但这一期望近日落空。FDA明确告知这家生物制药公司，需开展一项随机、双盲、假手术对照的III期临床试验。受此消息影响，公司股价周一收盘大跌约33%。根据公司发布的新闻稿，uniQure此前计划基于一项与外部对照比较的I/II期研究数据申请批准。uniQure表示，将在第二季度请求与FDA召开B类会议，商讨后续推进路径。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4139","LU0109394709.USD","LU0889565916.HKD","QURE","LU0320765992.SGD","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614581313","title":"Uniqure N.V.盘中异动 大幅下挫5.05%报16.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614581313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614581313?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:51","pubTimestamp":1772203867,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日22时51分，Uniqure N.V.股票出现异动，股价快速跳水5.05%。截至发稿，该股报16.25美元/股，成交量49.5034万股，换手率0.79%，振幅5.74%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.38%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022722510795424c0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022722510795424c0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614008551","title":"Uniqure N.V.股价重挫16.96% 市值涨5422.18万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614008551","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614008551?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:30","pubTimestamp":1772116209,"startTime":"0","endTime":"0","summary":"北京时间2026年02月26日22时30分，Uniqure N.V.股票出现异动，股价大幅跳水16.96%。截至发稿，该股报20.65美元/股，成交量202.299万股，换手率3.25%，振幅8.78%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.00%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226223010a722dad7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226223010a722dad7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","KAPA","LU0889565916.HKD","QURE","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611097942","title":"Uniqure N.V.盘中异动 临近午盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611097942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611097942?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:41","pubTimestamp":1770914514,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日00时41分，Uniqure N.V.股票出现波动，股价大幅下跌5.02%。截至发稿，该股报22.90美元/股，成交量65.1018万股，换手率1.05%，振幅6.06%。机构评级方面，在所有15家参与评级的机构中，80%的券商给予买入建议，20%的券商给予持有建议，无券商给予卖出建议。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.14%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021300415497a5fd47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021300415497a5fd47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","QURE","LU0320765992.SGD","BK4139","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603986676","title":"Uniqure N.V.盘中异动 下午盘大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986676?lang=zh_cn&edition=full","pubTime":"2026-01-15 02:30","pubTimestamp":1768415414,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日02时30分，Uniqure N.V.股票出现波动，股价快速上涨5.02%。截至发稿，该股报22.58美元/股，成交量82.5768万股，换手率1.33%，振幅6.74%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.17%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115023014953ccbf2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115023014953ccbf2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU0889565916.HKD","QURE","BK4139","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136475398","title":"异动解读 | 监管挑战致uniQure股价盘中大跌8.82%，AMT-130药物前景不明","url":"https://stock-news.laohu8.com/highlight/detail?id=1136475398","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136475398?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:03","pubTimestamp":1762787003,"startTime":"0","endTime":"0","summary":"周一盘中，生物技术公司uniQure N.V.股价大跌8.82%，主要原因是其用于治疗亨廷顿病的AMT-130药物面临监管挑战。尽管如此，uniQure管理层表示仍然相信AMT-130的潜力，并计划与FDA紧密合作推进该项目。除AMT-130外，uniQure的其他项目如AMT-260和AMT-191显示出早期临床进展，预计2026年会有更新数据。截至报告期末，uniQure拥有6.492亿美元现金储备，预计可支持运营至2029年。尽管公司整体财务状况稳健，但AMT-130的监管不确定性仍然是投资者关注的焦点，这也是导致股价大跌的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135225871","title":"uniQure 2025年第三季度业绩会总结及问答精华：AMT-130的监管挑战与未来展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1135225871","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135225871?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:01","pubTimestamp":1762786875,"startTime":"0","endTime":"0","summary":"公司仍然相信AMT-130的潜力，并计划与FDA紧密合作以推进该项目。研发费用增加至3440万美元，反映了AMT-130的BLA准备工作。现金储备为6.492亿美元，预计可支持运营至2029年。问题1：AMT-130的外部对照组是如何构建的？患者和医生社区对AMT-130充满期待，并积极合作推动项目进展。管理层对AMT-130的潜力充满信心，但对FDA的反馈表示失望和意外。AMT-162项目因剂量限制毒性暂停，需进一步评估。uniQure在2025年第三季度面临重大监管挑战，特别是AMT-130在亨廷顿病项目上的不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175225490","title":"uniQure盘初暴跌60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175225490","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175225490?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:44","pubTimestamp":1762181057,"startTime":"0","endTime":"0","summary":"周一，基因治疗公司 $uniQure N.V.(QURE)$ 暴跌60%。据报道，FDA表示该公司的一项重要症治疗方案的临床数据未达标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"64989c908af4d31938f65fabf9403946","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196508406","title":"uniQure N.V.在美上市股票盘前下跌66.2%，因FDA称其亨廷顿舞蹈症治疗临床数据不足","url":"https://stock-news.laohu8.com/highlight/detail?id=1196508406","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196508406?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:34","pubTimestamp":1762173298,"startTime":"0","endTime":"0","summary":"uniQure N.V.在美上市的股票在盘前交易中下跌了66.2%，原因是美国食品药品监督管理局（FDA）表示该公司的亨廷顿舞蹈症治疗方案的临床数据未达标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"64989c908af4d31938f65fabf9403946","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0889565916.HKD","QURE","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518086206","title":"Uniqure N.V.盘中异动 快速下挫5.07%报11.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518086206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518086206?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:08","pubTimestamp":1741630111,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时08分，Uniqure N.V.股票出现异动，股价快速下挫5.07%。截至发稿，该股报11.61美元/股，成交量35.4258万股，换手率0.66%，振幅4.29%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.70%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102083198a2d36f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102083198a2d36f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517145843","title":"Uniqure N.V.2024财年实现净利润-2.40亿美元，同比增加22.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517145843","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517145843?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363239,"startTime":"0","endTime":"0","summary":"3月8日，Uniqure N.V.公布财报，公告显示公司2024财年净利润为-2.40亿美元，同比增加22.08%；其中营业收入为27.12百万美元，同比增加71.21%，每股基本收益为-4.92美元。从资产负债表来看，Uniqure N.V.总负债5.63亿美元，其中短期债务3.60百万美元，资产负债比为0.99，流动比率为0.10。机构评级：截至2025年3月8日，当前有10家机构对Uniqure N.V.目标价做出预测，其中目标均价为36.20美元，其中最低目标价为18.00美元，最高目标价为70.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000100a2647e79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000100a2647e79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517195096","title":"Uniqure N.V.盘中异动 股价大涨5.05%报12.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517195096?lang=zh_cn&edition=full","pubTime":"2025-03-07 02:01","pubTimestamp":1741284074,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日02时01分，Uniqure N.V.股票出现波动，股价大幅拉升5.05%。截至发稿，该股报12.70美元/股，成交量40.313万股，换手率0.75%，振幅9.93%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.83%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307020115abebaa25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307020115abebaa25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170718364","title":"异动解读 | uniQure 公司股价盘中大涨5.08%,主要受公司业绩良好前景看好因素提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1170718364","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170718364?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:50","pubTimestamp":1741204219,"startTime":"0","endTime":"0","summary":"uniQure N.V.作为一家基因治疗公司,专注于开发用于治疗血友病、亨廷顿病等遗传性疾病的疗法,同时也与Bristol Myers Squibb合作开发心血管疾病的基因疗法。\n\n近期该公司公布的财报显示,尽管净利润为负,但营收同比有所增长,市场对公司长期发展前景保持看好。uniQure获得了12家机构的看好评级,有83%机构给予该股\"买入\"评级,也反映了机构对公司未来发展的乐观预期。\n\n因此,基于公司在基因治疗领域的前景获得认可,以及机构看好评级的影响,该公司股价在盘中出现了5.08%的大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | uniQure 公司股价盘中大涨5.08%,主要受公司业绩良好前景看好因素提振","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517259139","title":"Uniqure N.V.盘中异动 股价大涨5.08%报11.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517259139","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517259139?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:38","pubTimestamp":1741203506,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时38分，Uniqure N.V.股票出现波动，股价大幅拉升5.08%。截至发稿，该股报11.91美元/股，成交量46.6582万股，换手率0.86%，振幅6.84%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为2.02%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306033827963b1ea9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306033827963b1ea9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517460499","title":"HC Wainwright & Co.：重申uniQure(QURE.US)评级，由买入调整至买入评级, 目标价由70.00美元调整至70.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517460499","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517460499?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:23","pubTimestamp":1741108999,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申uniQure(QURE.US)评级，由买入调整至买入评级, 目标价由70.00美元调整至70.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05012348524101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516677148","title":"Uniqure N.V.盘中异动 早盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677148","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677148?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:47","pubTimestamp":1741099644,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时47分，Uniqure N.V.股票出现异动，股价快速跳水5.05%。截至发稿，该股报10.35美元/股，成交量7.0192万股，换手率0.13%，振幅4.40%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.45%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304224724abe7f4d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304224724abe7f4d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516375046","title":"Uniqure N.V.盘中异动 早盘大幅下跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516375046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516375046?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:52","pubTimestamp":1741013574,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时52分，Uniqure N.V.股票出现异动，股价快速下挫5.13%。截至发稿，该股报12.48美元/股，成交量3.2801万股，换手率0.06%，振幅5.82%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.06%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225254989a15a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225254989a15a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516317377","title":"富国银行：维持uniQure(QURE.US)评级，由持股观望调整至持股观望评级, 目标价由35.00美元调整至30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516317377","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516317377?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:31","pubTimestamp":1740763885,"startTime":"0","endTime":"0","summary":"富国银行：维持uniQure(QURE.US)评级，由持股观望调整至持股观望评级, 目标价由35.00美元调整至30.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01013148469986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378800","title":"Uniqure N.V.盘中异动 股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514378800?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753067,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Uniqure N.V.股票出现异动，股价急速下挫5.05%。截至发稿，该股报11.46美元/股，成交量2.3051万股，换手率0.04%，振幅0.00%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.02%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223107abe0ea00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223107abe0ea00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":0.143},{"period":"1month","weight":0.1935},{"period":"3month","weight":-0.2303},{"period":"6month","weight":-0.6969},{"period":"1year","weight":0.3523},{"period":"ytd","weight":-0.2654}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"uniQure N.V.作为私人有限责任公司于2012年1月9日依照荷兰相关法律条文成立。公司是一家专业从事基因治疗的生物技术企业，致力于为罕见病和重病患者开发单一治疗途径。其管线包括针对亨廷顿病、与SOD1突变相关的肌萎缩性侧索硬化症、难治性中位颞叶癫痫和法布里病的临床候选药物，反映了对推进基因治疗领域创新疗法的关注。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.5,"avgChangeRate":0.032875},{"month":3,"riseRate":0.307692,"avgChangeRate":-0.046417},{"month":4,"riseRate":0.461538,"avgChangeRate":0.022678},{"month":5,"riseRate":0.666667,"avgChangeRate":0.042965},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure N.V.","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供uniQure N.V.(QURE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"uniQure N.V.,QURE,uniQure N.V.股票,uniQure N.V.股票老虎,uniQure N.V.股票老虎国际,uniQure N.V.行情,uniQure N.V.股票行情,uniQure N.V.股价,uniQure N.V.股市,uniQure N.V.股票价格,uniQure N.V.股票交易,uniQure N.V.股票购买,uniQure N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供uniQure N.V.(QURE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}